Lenalidomide: what is the right dose in CLL?
نویسنده
چکیده
Ferrajoli and colleagues present the results of a phase 2 study in which lenalidomide was administered by continuous daily dosing to 44 patients with relapsed CLL. Clinical activity (ORR 32%, CR 7%) was observed, and responses were seen in patients with poor-risk cytogenetic abnormalities and unmutated IgVH. However, the mechanism(s) of action and the optimal dosing schedule of lenalidomide remain undefined.
منابع مشابه
Lenalidomide in chronic lymphocytic leukemia
Introduction: Chronic lymphocytic leukemia (CLL) is a complex disease. Insights into its pathogenesis and the interplay between B cell receptor (BCR) signaling and tumor microenvironment (TME) have provided newer therapeutic targets for the treatment of CLL. Lenalidomide is a 2 generation, immunomodulatory analogue with demonstrated clinical activity in CLL, both as an initial therapy and in pa...
متن کاملApproaches to Managing Safety With Lenalidomide in Hematologic Malignancies
Lenalidomide is an oral immunomodulatory agent approved in relapsed multiple myeloma with dexamethasone, for transfusion-dependent anemia in myelodysplastic syndrome associated with deletion 5q, and in relapsed/progressive mantle cell lymphoma following bortezomib. In recent clinical trials, lenalidomide has shown promising activity in hematologic malignancies, including chronic lymphocytic leu...
متن کاملLow Dose of Lenalidomide Enhances NK Cell Activity: Possible Implication as an Adjuvant
Background: Lenalidomide, a synthetic immunomodulatory drug, has a wide range of features including anti-angiogenic and anti-proliferative properties. To date, researchers have shown that lenalidomide is capable of ameliorating the immune system factors and antitumor responses. Most researchers have reported that lenalidomide enhances the immune response in certain cancer patients through sever...
متن کاملLenalidomide in the Treatment of Chronic Lymphocytic Leukemia
The application of nucleoside analogue-based chemotherapy and immunotherapy with rituximab or alemtuzumab has increased both response rate and survival in patients with Chronic Lymphocytic Leukemia (CLL). However, because none of these therapies is curative, sequential therapeutic regimens are required. The majority of patients with relapsed or refractory CLL carry poor prognostic factors and s...
متن کاملThe yin and yang of lenalidomide.
Lenalidomide is one of a series of immunomodulatory drugs (IMiDs) that have been tested in a variety of malignant and nonmalignant disorders. The history and application of this family of drugs dates back to the 1950s when thalidomide, a synthetic glutamic acid derivative, was initially developed as an anticonvulsant for the treatment of epilepsy. The IMiDs exhibit a multitude of biologic effec...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Blood
دوره 111 11 شماره
صفحات -
تاریخ انتشار 2008